Souhaitez-vous accéder aux communiqués récents ?

The results of the Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis were published in Gastroenterology,

Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring clinical data from the nebokitug Phase 2 trial in PSC.

Positive nebokitug PSC Phase 2 data was presented in an oral session at BSG Live’25, the scientific meeting of the British Society for Gastroenterology.

FDA agreement on CMC requirements and the timing of non-clinical toxicology testing are milestones further advancing nebokitug towards a PSC Phase 3 trial.

These major milestones in Q1 support advancement of Nebokitug to Phase 3 and position It to potentially become the first FDA-approved treatment for PSC.

Freiburg, den 7. Mai 2025 Die Studienergebnisse zeigen die Überlegenheit von Norucholsäure (NCA) gegenüber Placebo im kombinierten primären Endpunkt. Es gibt derzeit kein zugelassenes Arzneimittel...

Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary...

Positive data from the Phase 2 SPRING trial of nebokitug in PSC was presented in an oral Distinguished Abstract Plenary session at DDW 2025

David Weiner, MD, is rejoining Chemomab as Interim Chief Medical Officer and Clinical Development SVP Jack Lawler has been named Chief Development Officer.

Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis.